Skip to main content
Clinical Trials/NCT02814409
NCT02814409
Completed
Phase 3

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

NHS Greater Glasgow and Clyde1 site in 1 country1,858 target enrollmentDecember 15, 2016

Overview

Phase
Phase 3
Intervention
Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
Conditions
Ischemic Stroke
Sponsor
NHS Greater Glasgow and Clyde
Enrollment
1858
Locations
1
Primary Endpoint
modified Rankin Scale
Status
Completed
Last Updated
last year

Overview

Brief Summary

The principle research question is: in patients with acute ischaemic stroke eligible for intravenous (IV) thrombolysis, is tenecteplase superior in efficacy to alteplase, based on functional outcome as assessed by modified Rankin Scale distribution at day 90?

Registry
clinicaltrials.gov
Start Date
December 15, 2016
End Date
January 10, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Alteplase - standard care

Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).

Intervention: Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase

Tenecteplase

Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).

Intervention: Intravenous Tenecteplase

Outcomes

Primary Outcomes

modified Rankin Scale

Time Frame: Day 90 (+/- 7)

modified Rankin Scale (mRS) at day 90, determined by the Rankin Focused Assessment (RFA) method using centralised telephone interview, analysed by ordinal distribution ("shift") analysis of the scores in intervention and control groups.

Secondary Outcomes

  • Early major neurological improvement of 8 or more points, or return to the National Institutes of Health Stroke Scale (NIHSS) total score of 0 or 1 at 24 hour(s).(24 hours)
  • Health Related Quality of Life (EuroQol five dimensions questionnaire, EQ-5D)(Day 90 (+/- 7))
  • Barthel Index score(Day 90 (+/- 7))
  • Need for thrombectomy(24 hours)
  • Full neurological recovery (modified Rankin Scale 0-1 versus 2-6).(Day 90 (+/- 7))
  • Independent recovery (modified Rankin Scale score 0-2 versus 3-6).(Day 90 (+/- 7))

Study Sites (1)

Loading locations...

Similar Trials